CDH2 and cancer: Many studies have focused on the roleplayed by EMT activation in the invasion and metastasis of various cancertypes, both in vivo and invitro [50-53].Both the mesenchymal phenotype and EMT marker expression in cancer cells areassociated with chemo- [54], radio-[55], and immunotherapy[56] resistance, as well as reducedsusceptibility to apoptosis and aging signaling[57,58].Furthermore, elevated expressions of N-cadherin and vimentin are EMT markers that have beenfound to assist cancer cells in immune avoidance [59].